ArticleProceedings of the National Academy of Sciences of the United States of America1993
The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RARα.Cancer cell international · 2019Article
- RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance.Cancer cell international · 2019Article
- PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.Journal of cellular and molecular medicine · 2018Article
- Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.Oncogene · 2014Article
- HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse.EMBO molecular medicine · 2014Article
- Genome-wide functions of PML-RARα in acute promyelocytic leukaemia.British journal of cancer · 2011Review
- PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Computational identification of the normal and perturbed genetic networks involved in myeloid differentiation and acute promyelocytic leukemia.Genome biology · 2008Article
- Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia.Oncogene · 2006Article
- Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.Leukemia · 2003Article
- Variations on a theme: the alternate translocations in APL.Leukemia · 2002Review
- Nuclear DNA helicase II is recruited to IFN-alpha-activated transcription sites at PML nuclear bodies.The Journal of cell biology · 2002Article
- Review
- Transcriptional regulation in acute promyelocytic leukemia.Oncogene · 2001Review
- Cross-talk between glucocorticoid receptor and AP-1.Oncogene · 2001Review
- Review
- Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Article
- Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML.Molecular and cellular biology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report here that the fusion of PML, a nuclear protein defined by the t(15;17) chromosomal translocation in acute promyelocytic leukemia, with retinoic acid receptor alpha (RAR alpha) changes the RAR alpha from a retinoic acid (RA)-dependent inhibitor to a RA-dependent activator of AP-1 transcriptional activity. The PML-RAR alpha chimera cooperates with c-Jun and, strikingly, with c-Fos to stimulate the transcription of both synthetic and natural reporter genes containing an AP-1 site. Stimulation is dependent on the concentration of RA and its dose-response curve is comparable to that for activation by RAR alpha of transcription on RA-responsive genes. Further, in the absence of RA, a circumstance in which RAR alpha has no effect on AP-1 activity, PML-RAR alpha is an inhibitor. Deletion of the dimerization, transactivation, or DNA-binding domains of c-Jun and removal of the PML dimerization domain in the PML-RAR alpha hybrid abrogates their transcriptional cooperatively. In view of the association between AP-1 activity and hemopoietic differentiation, we suggest that these properties of PML-RAR alpha could contribute to the leukemic phenotype and its response to RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.